Pentamidine ( DrugBank: Pentamidine )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 61 | 自己免疫性溶血性貧血 | 1 |
| 65 | 原発性免疫不全症候群 | 1 |
61. 自己免疫性溶血性貧血
臨床試験数 : 137 / 薬物数 : 127 - (DrugBank : 55) / 標的遺伝子数 : 26 - 標的パスウェイ数 : 153
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2021-002844-66-IT (EUCTR) | 23/11/2021 | 23/09/2021 | Study of the Efficacy and Safety of Parsaclisib in Participants with Primary Warm Autoimmune Hemolytic Anemia | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants with Primary Warm Autoimmune Hemolytic Anemia - NA | Primary Warm Autoimmune Hemolytic Anemia MedDRA version: 20.0;Level: LLT;Classification code 10003825;Term: Autoimmune hemolytic anemia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Parsaclisib (1 mg) Product Code: [INCB050465] Other descriptive name: INCB050465 HYDROCHLORIDE Product Name: Parsaclisib (2.5 mg) Product Code: [INCB050465] Other descriptive name: INCB050465 HYDROCHLORIDE Product Name: trimethoprim-sulfamethoxazole Product Code: [trimethoprim-sulfamethoxazole] INN or Proposed INN: TRIMETOPRIM + SULFAMETOSSAZOLO * Product Name: pentamidine Product Code: [pentamidine] INN or Proposed INN: PENTAMIDINA ISETIONATO Product Name: atovaquone Product Code: [atovaquone] INN or Proposed INN: ATOVAQUONE | INCYTE CORPORATION | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 100 | Phase 3 | United States;Spain;Ukraine;Austria;Israel;United Kingdom;Italy;France;Canada;Belgium;Poland;Germany;Netherlands;Japan |
65. 原発性免疫不全症候群
臨床試験数 : 482 / 薬物数 : 653 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00803933 (ClinicalTrials.gov) | February 2003 | 4/12/2008 | Trial of DB289 for the Treatment of Stage I African Trypanosomiasis | Phase II b Trial of DB289 for the Treatment of Stage I African Trypanosomiasis | African Trypanosomiasis | Drug: DB289;Drug: Pentamidine | Immtech Pharmaceuticals, Inc | Bill and Melinda Gates Foundation | Completed | 15 Years | 50 Years | Both | 111 | Phase 2 | Congo |